The purpose of this study is to evaluate anti-oxidative and anti-inflammatory effects of pitavastatin in hypercholesterolemic patients with the metabolic syndrome.
The metabolic syndrome is defined as a cluster of cardiovascular risk factors including visceral obesity, dyslipidemia, elevated blood pressure and impaired glucose tolerance. Recently, it has been described that oxidative stress and inflammatory reaction, which are important in progression of atherosclerosis, increases in individuals with the metabolic syndrome. Statins might have beneficial effects such as anti-oxidative and anti-inflammatory actions that are independent from their cholesterol-lowering effects. Pitavastatin, a chemically synthesized statin, has potent LDL-cholesterol lowering and also anti-oxidative and anti-inflammatory effects in animal studies. However, the effects of pitavastatin on oxidative stress and inflammatory action in patients with the metabolic syndrome have not been reported.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Pitavastatin (2mg/day) was administered for 12 weeks
Tatsuaki Matsubara
Nagoya, Aichi-ken, Japan
Thiobarbituric acid reactive substance; high sensitive C-reactive protein
Time frame: 12 weeks
Total cholesterol; LDL-cholesterol; HDL-cholesterol; triglyceride;
Time frame: 12 weeks
Homeostasis model assessment for insulin resistance; adiponectin;
Time frame: 12 weeks
Soluble intercellular adhesion molecule-1
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.